The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009
Soluble guanylyl cyclase expression is reduced in acute lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 398s Year: 2006
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009
Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Resistive breathing reduces soluble guanylyl cyclase expression Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009
sGC activator BAY 412272 attenuates ischemia/reperfusion injury of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008
Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2009; 34: 731 Year: 2009
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Down-regulation of soluble guanylyl cyclase in asthma contributes to airway hyperreactivity Source: Eur Respir J 2005; 26: Suppl. 49, 581s Year: 2005
Endothelin-1 receptor antagonist prevents hyperoxia-induced parenchymal mechanical impairment in mice Source: Eur Respir J 2004; 24: Suppl. 48, 334s Year: 2004
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Resveratrol attenuates hypoxic pulmonary vascular remodeling in simulated high altitude-exposed rats: potential role of Hif-1α/NOX4/ROS inhibition Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Effects of soluble guanylate cyclase (sGC) stimulation in guinea pigs chronically exposed to cigarette smoke Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012
Soluble guanylate cyclase stimulators revert in vitro cigarette smoke effects through JNK pathway normalization Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021
Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rats Source: Annual Congress 2008 - Innovative treatments in sleep disordered breathing Year: 2008
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008